Alexis Leonard

发表

Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery

J. Tisdale, Selami Demirci, J. Haro-Mora, 2019, British journal of haematology.

Efficacy and safety of long-term sirolimus use as part of multidisciplinary care in a pediatric patient with CLOVES syndrome: Case report

L. Tosi, Yaser A Diab, Alexis Leonard, 2021, Translational Science of Rare Diseases.

Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models

Linhong Li, C. Allen, M. Peshwa, 2021, Cell reports. Medicine.

Low-Dose Busulfan Reduces Human CD34+ Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice

J. Tisdale, Selami Demirci, M. Hsieh, 2019, Molecular therapy. Methods & clinical development.

Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?

J. Tisdale, A. Abraham, Alexis Leonard, 2020, British journal of haematology.

High-Efficiency Lentiviral Transduction of Human CD34+ Cells in High-Density Culture with Poloxamer and Prostaglandin E2

J. Tisdale, Selami Demirci, M. Hsieh, 2019, Molecular therapy. Methods & clinical development.

Early initiation of inhaled corticosteroids does not decrease acute chest syndrome morbidity in pediatric patients with sickle cell disease.

R. McCarter, E. Meier, M. Sharron, 2018, Blood cells, molecules & diseases.

Debating the Future of Sickle Cell Disease Curative Therapy: Haploidentical Hematopoietic Stem Cell Transplantation vs. Gene Therapy

A. Kassim, Alexis Leonard, 2022, Journal of clinical medicine.

Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation

K. Keyvanfar, D. Malide, J. Tisdale, 2020, Stem Cell Research & Therapy.

A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease.

J. Tisdale, Alexis Leonard, 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.

Thomas E. Hughes, S. Tsai, D. Stroncek, 2020, Haematologica.

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor

Thomas E. Hughes, S. Tsai, M. Weiss, 2019, Haematologica.

Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease.

Thomas E. Hughes, S. Tsai, M. Weiss, 2021, Blood advances.

Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced

J. Tisdale, Alexis Leonard, 2018, Expert review of hematology.

Gene Therapy: The Path Toward Becoming a Realistic Cure for Sickle Cell Disease

A. Abraham, Alexis Leonard, Allistair A. Abraham, 2018 .

BCL11A enhancer edited hematopoietic stem cells persist in rhesus monkeys without toxicity.

Shondra M. Pruett-Miller, S. Tsai, S. Wolfe, 2020, The Journal of clinical investigation.

Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies.

J. Tisdale, Selami Demirci, Alexis Leonard, 2020, Human molecular genetics.

Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation.

Athena L. Russell, S. Prockop, J. Boelens, 2021, Cytotherapy.

Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor‐mobilized patients with sickle cell disease

S. Akel, J. Tisdale, M. Hsieh, 2022, British journal of haematology.

High-Grade Gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2012, Oxford Medicine Online.

Hematopoietic stem cells from pluripotent stem cells: Clinical potential, challenges, and future perspectives

J. Tisdale, Selami Demirci, Alexis Leonard, 2020, Stem cells translational medicine.

CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease

J. Tisdale, Selami Demirci, Alexis Leonard, 2021, Molecular therapy. Methods & clinical development.

CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.

J. Tisdale, Selami Demirci, J. Haro-Mora, 2019, Advances in experimental medicine and biology.

Etoposide improves survival in high-grade glioma: a meta-analysis.

J. Wolff, Alexis Leonard, 2013, Anticancer research.

Identification of red blood cell antibodies in maternal breast milk implicated in prolonged hemolytic disease of the fetus and newborn

D. Darbari, J. Webb, N. Luban, 2019, Transfusion.

Forced enhancer-promoter rewiring to alter gene expression in animal models

G. Blobel, B. Ryu, M. Weiss, 2023, Molecular therapy. Nucleic acids.

Clinical outcomes of children and adolescents with sickle cell disease and COVID-19 infection: A year in review at a metropolitan tertiary pediatric hospital

J. Barber, S. Majumdar, D. Darbari, 2023, Frontiers in Medicine.

Gene Therapy for Hemoglobinopathies: Beta-Thalassemia, Sickle Cell Disease.

J. Tisdale, Alexis Leonard, M. Bonner, 2022, Hematology/Oncology Clinics of North America.

High grade gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2022, Progress in Brain Research.

Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease

J. Tisdale, M. Hsieh, D. Darbari, 2022, Blood advances.

Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease

J. Tisdale, Alexis Leonard, Zaina Inam, 2023, Expert review of hematology.

Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.

S. Wolfe, A. Larochelle, Selami Demirci, 2024, Cytotherapy.